Bioxodes names new chairman, prepares pivotal stroke trial

Belgian biotech Bioxodes has appointed Philippe Monteyne as chairman of its board, replacing Pierre Detrixhe. The move comes as the company advances its lead candidate BIOX-101, a recombinant peptide for intracerebral hemorrhage, into a potentially registrational Phase IIb trial that could support conditional approvals in the USA and Europe.

Chief executive Marc Dechamps said Dr Monteyne’s industry background would be “invaluable” as the company targets commercialization, potentially by 2030. Phase IIa results recently showed BIOX-101 reduced hematoma volume and improved recovery signals compared with standard of care, supporting its potential as the first approved treatment for hemorrhagic stroke.

Dr Monteyne is a neurologist with extensive investment and executive experience, serving as senior advisor at AltamarCAM Partners and previously holding senior roles at SmithKline Beecham, GSK (LSE: GSK) and Sanofi (Euronext: SAN). At GSK he oversaw the launch of cervical cancer vaccine Cervarix (human papillomavirus vaccine), as well as programs leading to Strimvelis (autologous CD34+ cell enriched gene therapy) and Tegsedi (inotersen).